AGTR1 and cardiovascular disorder: Therefore, the ACE or AT1R blockers did not necessarily upregulate ACE2 expression in the lungs, and there was not enough reasons to stop taking ACE or AT1R inhibitors for SARS-CoV-2 infected patients with cardiovascular diseases.